Join
Live feed
·
INSIDERFilingvia Quantisnow
G1 Therapeutics Inc. logo

Chief Business Officer Avagliano Mark was granted 35,000 shares, increasing direct ownership by 17% to 244,683 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
GTHX· G1 Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GTHX (G1 Therapeutics Inc.) and more on Quantisnow.